Ongoing Therapy After CVP: For Low-Grade Indolent) Non-Hodgkin’s Lymphoma

For low-grade (indolent) non-Hodgkin’s lymphoma (NHL)

RITUXAN^® is indicated for the treatment of patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy.

Explore the clinical trial results, hear from RITUXAN patients, and get helpful resources.

Learn more

Indolent NHL: RITUXAN plus CVP for follicular NHL RITUXAN® is indicated: Follicular NHL: Initial Treatment; CVP THEN RITUXAN Ongoing Therapy for up to 2 years for low-grade NHL RITUXAN® is indicated for the treatment of patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy.; RITUXAN for treatment upon relapse of low-grade or follicular NHL RITUXAN® is indicated: Low-Grade or Follicular NHL: Relapsed

Aggressive NHL: RITUXAN plus CHOP for DLBCL RITUXAN® is indicated: DLBCL: Initial Treatment

View a video introduction featuring former NFL player Merril Hoge.

The Rituxan Support Center

Gain access to information about NHL and Rituxan. Speak to a nurse educator 24 hours a day, 7 days a week.

This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.

INDICATIONS and IMPORTANT SAFETY INFORMATION

RITUXAN^® is indicated for the treatment of patients with:

Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens

Important Safety Information

RITUXAN^® can cause serious side effects, some of which can be life-threatening, including: progressive multifocal leukoencephalopathy (PML), infusion reactions, tumor lysis syndrome (TLS), and severe skin reactions. Other serious and life-threatening side effects with RITUXAN include: hepatitis B virus reactivation, heart problems, infections, and stomach and bowel problems. Common side effects during RITUXAN infusions include: fever, headache, chills and shakes, nausea, itching, hives, cough, sneezing, and throat irritation or tightness.

Tell your doctor about any side effects that bother you or that do not go away. These are not all of the possible side effects with RITUXAN. Ask your doctor for more information.

Please read the Medication Guide in HTML or PDF versions and the full prescribing information for more information.